As per the analyst, the transformation consists of inventory and debt reduction, and divestitures, together with an agile organizational structure ... Eastman Chemical Company (NYSE:EMN) operates ...

Six years before the start of the COVID-19 pandemic, an Ebola outbreak in West Africa had people fearing the possibility of a ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Purdue University scientists have discovered a key mechanism that regulates how plants develop chloroplasts, essential ...

A natural antibacterial molecule shows clinical promise. Its unusual binding site is on an excellent target: ...

Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the Australian biotech to consider its own future. The drug in question is sozinibercept, an inhibitor of vascular ...

The new molecular structure is, in the nomenclature of researchers, a “sandwich.” In this formation, a berkelium atom, serving as the filling, lays in between two 8-membered carbon rings — t ...

Strategic initiatives include launching biosimilars for Prolia, Symphony, and EYLEA, and exploring a potential listing on the Stockholm Exchange.

A mid-stage trial of 4D Molecular Therapeutics gene therapy for ... plus a reduced need for injections into the eye with current therapy Eylea. On the strength of the results, 4DMT is planning ...

By 2028, Alvotech aims to achieve $1.5 billion in revenues and a 40-45% EBITDA margin. Strategic initiatives include launching biosimilars for Prolia, Symphony, and EYLEA, and exploring a potential ...

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...